Restoring Health, Transforming Lives Through Innovation
ZyVersa is committed to improving health outcomes and quality of life for patients with inflammatory and renal diseases
Inflammasomes are molecular complexes that activate the innate immune system. Although the immune system is critical for health, excessive and/or chronic activation can result in inflammatory diseases. ZyVersa is developing IC 100, a novel monoclonal antibody that inhibits a component of the inflammasome (adaptor ASC) to block initiation and perpetuation of the inflammatory cascade.
Learn moreAlthough cholesterol is critical for healthy cells, in chronic kidney diseases excess cholesterol accumulates in the kidney's filtration system due to impaired transport out of the cells. This impairs the structure and function, resulting in protein spillage into the urine. ZyVersa is developing VAR 200, a cholesterol efflux mediator that removes excess cholesterol from the kidney's filtration system to protect against structural damage, reduce proteinuria, and preserve function.
Learn More